Recent clinical trials have demonstrated that combining programmed cell death protein 1 (PD-1) inhibitors with chemotherapy improves survival in patients with HER2-negative G/GEJ adenocarcinoma (10–14). The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.